Anti-Malarial Drug Market Synopsis

Anti-Malarial Drug Market Size Was Valued at USD 1034.24 Million in 2023 and is Projected to Reach USD 1563.66 Million by 2032, Growing at a CAGR of 4.7% From 2024-2032.

Antimalarial Drugs are a type of antiparasitic chemical agent, that are often naturally derived and can be used to treat or prevent malaria.

• Anti-malarial drugs are very much essential for the treatment of malaria. They help to kill the Plasmodium parasites which are responsible for the infection and alleviate the symptoms associated with the disease. Timely administration of these drugs can save lives and prevent severe complications.
• They are also used for prevention purposes, particularly in regions where malaria is endemic, People living in or traveling to such areas may take prophylactic doses of these drugs to reduce the risk of contracting the disease.
• The drug-resistant strains of malaria parasites are a challenge in the fight against malaria hence, Anti-malarial drugs, including combination therapies, are designed to combat drug-resistant strains and prevent the further spread of resistance.
• The research and development of new anti-malarial drugs like Sulfadoxine-pyrimethamine and many others are also taking place to stay ahead of drug resistance and improve treatment options.

Top Active Players Involved are:

“Abbott Laboratories (USA), Astellas Pharma (Japan), AstraZeneca (UK), Bayer (Germany), Boehringer Ingelheim (Germany), Bristol Myers Squibb (USA), Cipla (India), Daiichi Sankyo (Japan), Dr. Reddy's Laboratories (India), Eisai Co., Ltd. (Japan), Gilead Sciences (USA), GlaxoSmithKline (GSK) (UK), Grifols (Spain), Johnson & Johnson (USA), Lupin Limited (India), Mallinckrodt Pharmaceuticals (USA), Merck & Co. (USA), Mylan (USA), Novartis (Switzerland), Pfizer (USA), Roche (Switzerland), Sanofi (France), Sun Pharmaceutical Industries (India), Guilin Pharmaceutical Co. Ltd (China), Teva Pharmaceutical Industries (Israel) and Other Active Players.”

Anti-Malarial Drug Market Trend Analysis

Increase in Prevalence of Malaria

• The rise in the cases of malaria increased the demand for effective anti-malarial drugs. This creates a larger market for pharmaceutical companies and encourages investment in research and development for new and improved treatments.
• The growth of the market for anti-malarial products is offering chances for current companies to broaden their range of products. They can bring in new formulations, combination therapies, or innovative methods of drug delivery to meet the increasing demands of patients and healthcare providers.
• The rise in the need for anti-malarial medications encourages creativity and rivalry within the industry. Pharmaceutical companies are required to create drugs that are more effective, and affordable.
• The increase in malaria cases motivates partnerships among pharmaceutical firms, research centers, and global health entities can result in collaborative initiatives to create and distribute medications for malaria prevention.
• The increasing number of malaria cases frequently leads governments to invest in healthcare facilities and budget for programs to control the disease. These measures have the potential to establish a conducive setting for the market of anti-malarial products.

Opportunity

The rising government initiatives and investments

• The government is frequently providing more financial support for efforts to control and prevent malaria. This provides chances for pharmaceutical companies and researchers to secure funding for creating and manufacturing new anti-malarial medications.
• Their goal is to enhance healthcare systems, specifically in areas where malaria is prevalent. This could result in the creation or enhancement of medical facilities and the assignment of skilled medical staff.
• They are collaborating with private organizations, such as pharmaceutical companies, to tackle public health issues such as malaria, these can improve the accessibility and cost of anti-malarial medications.
• They have a major role in overseeing drug quality, safety, and effectiveness. They are establishing criteria and regulations for pharmaceutical companies to follow when developing and producing drugs. They are participating in educational initiatives to promote knowledge on preventing, diagnosing, and treating malaria.

Anti-Malarial Drug Market Segment Analysis:

Anti-Malarial Drug Market Segmented on the basis of Drug Class, Malaria Type, Mechanism of Action.

By Drug Class, Artemisinin Compounds Segment Is Expected to Dominate the Market During the Forecast Period

• Artemisinin compounds like Artemether and Artesunate are well known for their high efficacy against malaria parasites, including drug-resistant strains. They exhibit rapid action and reduce the parasite load in infected individuals.
• The World Health Organization also recommends the use of Artemisinin-based Combination Therapies as first-line treatment for this uncomplicated malaria.
• These compounds are typically used as part of combination therapy, where they are paired with other anti-malarial drugs, this helps to prevent the emergence of resistance and increases treatment efficacy.
• Various global initiatives and programs like the Roll Back Malaria Partnership, prioritize the use of Artemisinin-based Combination Therapies (ACTs) as part of their strategies to combat malaria.
• The Continuous research and development efforts focus on optimizing Artemisinin compounds, such as developing new formulations or combination therapies. This ongoing innovation is also supporting the market dominance of Artemisinin compounds.

By Mechanism of Action, Prevention from Malaria Segment Held the Largest Share In 2023

• Preventing malaria is essential for lessening the impact of the disease. Governments, global healthcare authorities, and international organizations are also prioritizing preventive measures with great importance.
• In areas where malaria is common, prevention is an important tactic for lowering disease transmission. Commonly prescribed medications like Chloroquine, Doxycycline, and Atovaquone/Proguanil are given to people who are either traveling to or residing in regions where malaria is prevalent.
• The demand for anti-malarial drugs is largely driven by the travel medicine industry. People who visit countries where malaria is common often look for preventive medication to stay safe during their journey.
• The significance of malaria prevention is highlighted in public health campaigns and educational efforts, especially for those who are more susceptible. These initiatives are focused on raising knowledge about the use of preventative medicines and implementing other preventive actions, thereby increasing the need for antimalarial medications.
• Healthcare authorities, such as the World Health Organization (WHO), suggest certain anti-malarial medications for prevention according to regional guidelines and resistance patterns of malaria. Hence in this way, Prevention from Malaria acts as a dominating segment in the anti-malarial Drug Market.

Anti-Malarial Drug Market Regional Insights:

Middle East & Africa is Expected to Dominate the Market Over the Forecast Period

• Several countries in the Middle East Africa region, particularly in Sub-Saharan Africa, have a high malaria burden. They contribute significantly to global malaria cases and require substantial anti-malarial interventions.
• This is home to a large population, providing a substantial consumer base for anti-malarial drugs. The size of the population presents opportunities for market growth and investment in the region.
• Efforts have been made to improve access to healthcare services in this region, including the availability of anti-malarial drugs.
• Governments in this region, along with international organizations, have initiated various malaria control programs and interventions. These include distributing anti-malarial drugs, implementing prevention strategies, and supporting treatment services.
• The MEA region forms a popular destination for international tourists. Travelers visiting countries with a malaria risk seek anti-malarial medications for prevention. Hence, in this way, Middle East Africa acts as a dominating region in the Anti-Malarial Drug Market.

• Africa is the region most affected by malaria in the world. The total number of reported deaths due to the disease was roughly 1,05,000 deaths in 2023. The Democratic Republic of Congo registered the highest amount, nearly 25,100 fatalities, followed by Angola, with some 12,860 deaths.

Anti-Malarial Drug Market Active Players

• Abbott Laboratories (USA)
• Astellas Pharma (Japan)
• AstraZeneca (UK)
• Bayer (Germany)
• Boehringer Ingelheim (Germany)
• Bristol Myers Squibb (USA)
• Cipla (India)
• Daiichi Sankyo (Japan)
• Reddy's Laboratories (India)
• Eisai Co., Ltd. (Japan)
• Gilead Sciences (USA)
• Glaxosmithkline (Gsk) (UK)
• Grifols (Spain)
• Johnson & Johnson (USA)
• Lupin Limited (India)
• Mallinckrodt Pharmaceuticals (USA)
• Merck & Co. (USA)
• Mylan (USA)
• Novartis (Switzerland)
• Pfizer (USA)
• Roche (Switzerland)
• Sanofi (France)
• Sun Pharmaceutical Industries (India)
• Guilin Pharmaceutical Co. Ltd (China)
• Teva Pharmaceutical Industries (Israel) And Other Active Players.

Key Industry Developments in the ANTI-MALARIAL DRUG Market:

• In April 2024, USAID (U.S Agency for International Development) Launched New Partnerships to Support Malaria Prevention, Strengthen Infrastructure, and Bolster Food Security in Angola. This provides financial and technical assistance that enables the Government of the Republic of Angola to deploy life-saving interventions proven to fight against malaria.
• In October 2023, The University of Oxford and the Serum Institute of India developed a malaria vaccine named Oxford R21/Matrix-M™ which also received WHO recommendation to use and demonstrates high efficacy to treat the Malaria Patients.